The Michigan-based company, founded in 2015, is in the clinical stage of developing MSDC-0602K, a next-gen insulin sensitizer that resolves the underlying pathophysiology of NASH. The sensitizer drug is currently undergoing Phase 2b clinical trials and has the potential to treat liver and metabolic diseases by avoiding the recurrence of nonalcoholic steatohepatitis, a life-threatening condition characterized by liver inflammation, fibrosis, and cancer.